CARMENA Trial Randomized Patients | Either Tyrosine-Kinase Inhibitor, or Surgery & Sunitnib

CARMENA Trial Randomized Patients | Either Tyrosine-Kinase Inhibitor, or Surgery & Sunitnib

Annual-Meeting

1 year
180 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Aly-Khan A. Lalani, MD, FRCPC Juravinski Cancer Centre, explains CARMENA Trial Randomized Patients | Either Tyrosine-Kinase Inhibitor, or Surgery & Sunitnib at Annual Meeting 2018
Up Next Autoplay
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
11 Views
kidneycancer 1 day
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
8 Views
kidneycancer 1 day
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
8 Views
kidneycancer 3 days
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
10 Views
kidneycancer 4 days
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Using Epigenetic Therapy to Enhance Immunotherapy Response in RCC
Category: Kidney Cancer
8 Views
kidneycancer 4 days
Therapeutic targeting of the extracellular matrix in kidney cancer
Therapeutic targeting of the extracellular matrix in kidney cancer
Category: Kidney Cancer
7 Views
kidneycancer 4 days
Innate Cytokines and Myeloid Cells
Innate Cytokines and Myeloid Cells
Category: Kidney Cancer
58 Views
kidneycancer 4 days
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
DNA Demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells
Category: Kidney Cancer
3 Views
kidneycancer 4 days
The T-cell response to Kidney Cancer
The T-cell response to Kidney Cancer
Category: Kidney Cancer
5 Views
kidneycancer 4 days
Discovery of new IO Targets Leveraging CRISPR
Discovery of new IO Targets Leveraging CRISPR
Category: Kidney Cancer
4 Views
kidneycancer 4 days